Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The proprietary CEACAM1 antibodies are having a direct co-stimulatory effect on immune cells in addition to interfering with the CEACAM1-CEACAM mediated check-point blockade.

Products, services, technology

Monoclonal Antibodies directed against CEACAM (Carcinoembryonic Antigen-related Cell Adhesion Molecules)

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business